Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase

被引:490
|
作者
Mol, CD [1 ]
Dougan, DR
Schneider, TR
Skene, RJ
Kraus, ML
Scheibe, DN
Snell, GP
Zou, H
Sang, BC
Wilson, KP
机构
[1] Syrrx Inc, San Diego, CA 92121 USA
[2] Italian Fdn Canc Res, Inst Mol Oncol, I-20139 Milan, Italy
关键词
D O I
10.1074/jbc.M403319200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The activity of the c-Kit receptor protein-tyrosine kinase is tightly regulated in normal cells, whereas deregulated c-Kit kinase activity is implicated in the pathogenesis of human cancers. The c-Kit juxtamembrane region is known to have an autoinhibitory function; however the precise mechanism by which c-Kit is maintained in an autoinhibited state is not known. We report the 1.9-Angstrom resolution crystal structure of native c-Kit kinase in an autoinhibited conformation and compare it with active c-Kit kinase. Autoinhibited c-Kit is stabilized by the juxtamembrane domain, which inserts into the kinase-active site and disrupts formation of the activated structure. A 1.6-Angstrom crystal structure of c-Kit in complex with STI-571 ( Imatinib(R) or Gleevec(R)) demonstrates that inhibitor binding disrupts this natural mechanism for maintaining c-Kit in an autoinhibited state. Together, these results provide a structural basis for understanding c-Kit kinase autoinhibition and will facilitate the structure-guided design of specific inhibitors that target the activated and autoinhibited conformations of c-Kit kinase.
引用
收藏
页码:31655 / 31663
页数:9
相关论文
共 50 条
  • [31] A new ELISA for cellular c-kit phosphorylation: Activity of STI571 compared to that of other protein kinase inhibitors.
    Mestan, E
    Kempf, D
    Goutte, G
    Fletcher, JA
    Manley, P
    BLOOD, 2003, 102 (11) : 169B - 169B
  • [32] STI571治疗C-Kit阳性肿瘤的研究进展
    孟利花
    马梁明
    白血病淋巴瘤., 2005, (02) : 127 - 128
  • [33] The ARG tyrosine kinase is inhibited by STI571.
    Okuda, K
    Weisberg, E
    Gilliland, DG
    Griffin, JD
    BLOOD, 2000, 96 (11) : 344A - 344A
  • [34] c-Kit tyrosine kinase receptor:: a new analgesic target?
    Marmigere, Frederic
    Scamps, Frederique
    Valmier, Jean
    M S-MEDECINE SCIENCES, 2008, 24 (05): : 464 - 466
  • [35] c-Kit - A hematopoietic cell essential receptor tyrosine kinase
    Edling, Charlotte E.
    Hallberg, Bengt
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2007, 39 (11): : 1995 - 1998
  • [36] STI571:: Bcr-Abl kinase inhibition as the basis of therapy for CML
    Mauro, MJ
    Druker, BJ
    LEUKEMIA, 2001, 15 (03) : 488 - 488
  • [37] Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors
    Buchdunger, E
    Cioffi, CL
    Law, N
    Stover, D
    Ohno-Jones, S
    Druker, BJ
    Lydon, NB
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2000, 295 (01): : 139 - 145
  • [38] Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition
    Kronnie, GT
    Timeus, F
    Rinaldi, A
    Crescenzio, N
    Spinelli, M
    Rosolen, A
    Ricotti, E
    Basso, G
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2004, 14 (03) : 373 - 382
  • [39] STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
    Tuveson, DA
    Willis, NA
    Jacks, T
    Griffin, JD
    Singer, S
    Fletcher, CDM
    Fletcher, JA
    Demetri, GD
    ONCOGENE, 2001, 20 (36) : 5054 - 5058
  • [40] STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
    David A Tuveson
    Nicholas A Willis
    Tyler Jacks
    James D Griffin
    Samuel Singer
    Christopher DM Fletcher
    Jonathan A Fletcher
    George D Demetri
    Oncogene, 2001, 20 : 5054 - 5058